Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | NNMT | P40261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8301007 | 0.84 | — | — | |
| SCHEMBL13411343 | 0.82 | — | — | |
| SCHEMBL1911881 | 0.82 | — | — | |
| SCHEMBL25706059 | 0.82 | — | — | |
| SCHEMBL374406 | 0.82 | — | — | |
| SCHEMBL29741837 | 0.82 | — | — | |
| SCHEMBL29382825 | 0.82 | — | — | |
| SCHEMBL3675179 | 0.82 | — | — | |
| SCHEMBL17581198 | 0.82 | — | — | |
| SCHEMBL17625100 | 0.82 | CYP1A2 (0.41) | CYP1A2CLK4CYP2D6HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104672311-A | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH INC | 2015-06-03 | — | — | CN | claimed |
| EP-0430196-B1 | Process for stabilization of high-chloride crystals with modified crystal habit using bromide shells | DU PONT (US) | 1995-03-22 | — | — | EP | claimed |
| EP-0288949-B1 | PROCESS FOR THE PREPARATION OF TABULAR SILVER CHLORIDE EMULSIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-28 | — | — | EP | claimed |
| US-5035992-A | Precipiating on cores | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-30 | — | — | US | claimed |
| EP-0430196-A1 | Process for stabilization of high-chloride crystals with modified crystal habit using bromide shells | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-06-05 | — | — | EP | claimed |
| EP-0304908-B1 | PROCESS FOR THE PREPARATION OF OCTAHEDRAL SILVER CHLORIDE-CONTAINING EMULSIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-03-20 | — | — | EP | claimed |
| EP-0304908-A1 | Process for the preparation of octahedral silver chloride-containing emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-03-01 | — | — | EP | claimed |
| US-4804621-A | USING A GELATIN DISPERSION AND AN ORGANIC HETEROCYCLIC COMPOUND SUCH AS AN AMINO-AZA-PYRIMIDINE OR-S-TRIAZINE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-02-14 | — | — | US | claimed |
| US-4801523-A | HETEROCYCLIC NITROGEN COMPOUND AS CRYSTAL MODIFIER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-01-31 | — | — | US | claimed |
| EP-0288949-A2 | Process for the preparation of tabular silver chloride emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-02 | — | — | EP | claimed |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | disclosed |
| WO-2015091584-A1 | THIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS TYK2 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| WO-2007024754-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | AMGEN INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-7179885-B2 | Silver-dispersing polypeptides | FUJI PHOTO FILM B.V. (NL) | 2007-02-20 | — | — | US | disclosed |
| US-20040048208-A1 | Silver-dispersing polypeptides | FUJI FILM MANUFACTURING EUROPE B.V. (NL) | 2004-03-11 | — | — | US | disclosed |
| EP-0304908-B1 | PROCESS FOR THE PREPARATION OF OCTAHEDRAL SILVER CHLORIDE-CONTAINING EMULSIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-03-20 | — | — | EP | disclosed |
| EP-0304908-A1 | Process for the preparation of octahedral silver chloride-containing emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4804621-A | USING A GELATIN DISPERSION AND AN ORGANIC HETEROCYCLIC COMPOUND SUCH AS AN AMINO-AZA-PYRIMIDINE OR-S-TRIAZINE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-02-14 | — | — | US | disclosed |
| US-4801523-A | HETEROCYCLIC NITROGEN COMPOUND AS CRYSTAL MODIFIER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0288949-A2 | Process for the preparation of tabular silver chloride emulsions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | CYP1A2 4529/4885CLK4 4302/4885CYP2D6 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.